Project Details
Description
Narrative
A barrier to developing effective strategy for control of disease caused by Mycobacterium tuberculosis
(Mtb) is the exceptional ability of this pathogen to evade host immune responses. We propose that Mtb
circumvents some immune defenses by activating an immunosuppressive pathway controlled by a host
enzyme called indoleamine 2,3-dioxygenase (IDO). We have found that IDO contributes to the control of
the pathological process in Mtb infection, and likely promotes the transmission of the bacteria. Studies will
be carried out to gain a full understanding of how IDO regulates the development of immunopathology in an
Mtb-infected host, and the information obtained will be applied to strategies for improving vaccination and
host-directed therapies against this infection.
Status | Finished |
---|---|
Effective start/end date | 5/1/18 → 4/30/22 |
Funding
- National Institute of Allergy and Infectious Diseases: $302,490.00
- National Institute of Allergy and Infectious Diseases: $503,978.00
- National Institute of Allergy and Infectious Diseases: $299,905.00
- National Institute of Allergy and Infectious Diseases: $806,468.00
- National Institute of Allergy and Infectious Diseases: $806,468.00
- National Institute of Allergy and Infectious Diseases: $806,468.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.